OBJECTIVE: To explore the efficacy of Xuanbai Chengqi Decoction combined with conventional Western medicine in the treatment of AECOPD patients with phlegm-heat obstructing the lung syndrome. METHODS: A retrospective analysis was conducted on the clinical data of 166 patients with this syndrome admitted to our hospital between December 2023 and March 2024. Patients were divided into a study group (Xuanbai Chengqi Decoction + conventional Western medicine treatment, 83 cases) and a control group (conventional Western medicine treatment, 83 cases). The clinical efficacy, Traditional Chinese Medicine (TCM) syndrome scores, blood routine indicators, inflammatory factors, and other clinical outcomes were compared between the two groups. RESULTS: Before treatment, there were no significant differences in the above-mentioned indicators between the two groups (P >
0.05). After treatment, the study group showed a significantly higher overall effective treatment rate, lymphocyte percentage, SOD, and NO levels, and a significantly lower TCM syndrome score, neutrophil percentage, white blood cell count, TNF-α, IL-6, CRP, and MOD levels, with statistical significance (P <
0.05). CONCLUSION: Xuanbai Chengqi Decoction combined with Western medicine treatment can effectively alleviate the clinical symptoms of AECOPD patients with phlegm-heat obstructing the lungs syndrome, improve blood routine indicators, control inflammation, and enhance the overall therapeutic effect.